Skip to main content

Table 3 Overall response rates, cytokine release syndrome, and neurotoxicity associated with selected cellular-directed therapy

From: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Antigen Product name (NCT) Study enrollment (n) Median time to follow-up (months) Overall response rate (%) Cytokine release syndrome (%) Neurotoxicity (%)
CAR-T cells       
BCMA JNJ-68284528 (NCT03548207) 97 8.8 95 95 21
BCMA bb21217 (NCT03274219) 46 8.5 55 67 22
BCMA /CD19 GC012F (NCT04236011) 16 7.3 94 88 0
BCMA/CD38 BM 38CAR (ChiCTR1800018143) 16 9.0 87.5 62.5 0
BCMA ALLO-715 (NCT04093596) 19 2.0 60 24 0
Bispecific antibody (BiTE)       
BCMA × CD3 Teclistamab JNJ-64007957 (NCT03145181) 128 n/a 64 53 5
BCMA × CD3 CC-93269 (NCT03486067) 19 3.7 83.3 89.5 n/a
BCMA × CD3 PF-06863135 (NCT03269136) 18 n/a 33 61 n/a
BCMA × CD3 TNB-383B (NCT03933735) 38 n/a 37 21 13 (headache)
BCMA × CD3 REGN5458 (NCT03761108) 45 2.4 36 38  ≥ 1
GPRC5D × CD3 Talquetamab JNJ-64407564 (NCT03399799) 137 n/a 78 47 5
FcRH5 × CD3 BFCR4350A (NCT03275103) 51 6.2 52 75 n/a